Genitourinary: DAD-IO
Trial ID
04724018
Trial Sponsor
Dana Farber Cancer Institute
Combinations of Sacituzumab govitecan plus enfortumab vedotin and pembrolizumab for metastatic urothelial carcinoma: the Double Antibody Drug conjugate (DAD) and Double Antibody Drug Conjugate with Immunotherapy Phase I/II trial